Cyagen: Cyagen and Neurophth partner to develop gene therapy vectors
Cyagen is entitled to get research and clinical phase milestone payments, as well as royalty payments totalling over $140m. The post Cyagen and Neurophth partner to develop gene therapy vectors appeared first on Pharmaceutical Technology.
Read full article »
Cyagen is a bioscience company that provides DNA vector construction, BAC recombineering, transgenic mice generation and virus packaging services.
Read more